BRPI0915119B8 - uso de iota carragenano - Google Patents
uso de iota carragenanoInfo
- Publication number
- BRPI0915119B8 BRPI0915119B8 BRPI0915119A BRPI0915119A BRPI0915119B8 BR PI0915119 B8 BRPI0915119 B8 BR PI0915119B8 BR PI0915119 A BRPI0915119 A BR PI0915119A BR PI0915119 A BRPI0915119 A BR PI0915119A BR PI0915119 B8 BRPI0915119 B8 BR PI0915119B8
- Authority
- BR
- Brazil
- Prior art keywords
- carrageenan
- iota
- therapeutic agents
- relates
- treatment
- Prior art date
Links
- 229940113118 carrageenan Drugs 0.000 title abstract 6
- 235000010418 carrageenan Nutrition 0.000 title abstract 6
- 229920001525 carrageenan Polymers 0.000 title abstract 6
- 239000000679 carrageenan Substances 0.000 title abstract 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 title abstract 6
- 239000003814 drug Substances 0.000 abstract 3
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
uso de iota carragenano a presente invenção refere-se a composições farmacêuticas com base em carragenano como um ingrediente ativo, para uso como um medicamento no tratamento profilático ou terapêutico de condições ou de doenças alérgicas, com a condição de que o carragenano compreende iota e/ou kappa carragenano e é substancialmente livre de lambda carragenano. tipicamente, a invenção refere-se a formulações líquidas, géis e a composições em pó seco que compreendem iota e/ou kappa carragenano e, opcionalmente, um ou mais agentes terapêuticos para administração ao trato respiratório, ao trato gastrintestinal ou aos olhos. foi descoberto que as composições da invenção são eficazes na prevenção e no tratamento de alergias do tipo i e adicionalmente podem exercer uma função adjuvante por administração combinada às mucosas com agentes terapêuticos sem ser de carragenano.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12950708P | 2008-07-01 | 2008-07-01 | |
| US61/129507 | 2008-07-01 | ||
| PCT/EP2009/004696 WO2010000437A1 (en) | 2008-07-01 | 2009-06-30 | Antiallergic marine biopolymers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0915119A2 BRPI0915119A2 (pt) | 2016-02-10 |
| BRPI0915119B1 BRPI0915119B1 (pt) | 2021-02-17 |
| BRPI0915119B8 true BRPI0915119B8 (pt) | 2021-05-25 |
Family
ID=41127843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0915119A BRPI0915119B8 (pt) | 2008-07-01 | 2009-06-30 | uso de iota carragenano |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20110091583A1 (pt) |
| EP (1) | EP2303287B1 (pt) |
| JP (1) | JP5687619B2 (pt) |
| CN (1) | CN102065869B (pt) |
| AU (1) | AU2009266076B2 (pt) |
| BR (1) | BRPI0915119B8 (pt) |
| CA (1) | CA2726221C (pt) |
| DK (1) | DK2303287T3 (pt) |
| EA (1) | EA020222B1 (pt) |
| ES (1) | ES2445870T3 (pt) |
| HR (1) | HRP20140164T1 (pt) |
| MX (1) | MX2010013567A (pt) |
| NZ (1) | NZ589293A (pt) |
| PL (1) | PL2303287T3 (pt) |
| PT (1) | PT2303287E (pt) |
| SG (1) | SG191697A1 (pt) |
| SI (1) | SI2303287T1 (pt) |
| WO (1) | WO2010000437A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006795A2 (en) | 2011-07-07 | 2013-01-10 | Humanitas International Foundation | Antiviral compositions and methods of their use |
| DE102013000699A1 (de) * | 2012-10-04 | 2014-04-10 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Zusammensetzung, insbesondere pharmazeutische Zusammensetzung, insbesondere zur Verabreichung bei Heiserkeit |
| MX383779B (es) * | 2013-03-15 | 2025-03-14 | Hyprotek Inc | Dispositivo de inyección de múltiples cámaras. |
| CN103301065A (zh) * | 2013-06-27 | 2013-09-18 | 辽宁亿灵科创生物医药科技有限公司 | 一种海藻提取物的鼻喷剂及其制备方法 |
| HUE045990T2 (hu) | 2013-12-03 | 2020-02-28 | Gerolymatos Int S A | Ionos vizes készítmények |
| DK2898888T3 (da) * | 2014-01-22 | 2019-06-03 | Visufarma B V | Sammensætning omfattende iota-carrageenan mod viral konjunktivitis |
| CN104147603A (zh) * | 2014-08-04 | 2014-11-19 | 辽宁亿灵科创生物医药科技有限公司 | 一种新型海藻提取物组合物在预防病毒性感冒中的应用 |
| AR108280A1 (es) * | 2016-05-05 | 2018-08-08 | Acraf | Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo |
| CN108498473A (zh) * | 2018-06-28 | 2018-09-07 | 哈尔滨珍宝制药有限公司 | 一种包含孟鲁司特钠的药物组合物及其制备方法和用途 |
| CN108498474A (zh) * | 2018-06-28 | 2018-09-07 | 哈尔滨珍宝制药有限公司 | 一种包含盐酸曲美他嗪的药物组合物及其制备方法和用途 |
| EP4623919A1 (en) * | 2024-03-28 | 2025-10-01 | Marinomed Biotech AG | Composition comprising iota-carrageenan for the treatment of dry eyes, non-viral conjunctivitis and allergic ocular conditions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6244265B1 (en) * | 1997-01-29 | 2001-06-12 | Peter J. Cronk | Adhesively applied external nasal strips and dilators containing medications and fragrances |
| US6447816B1 (en) * | 2000-04-03 | 2002-09-10 | Inhalation, Inc. | Methods and apparatus to prevent colds, flus, and infections of the human respiratory system |
| FR2808687B1 (fr) * | 2000-04-27 | 2003-12-05 | Goemar Lab Sa | Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose |
| WO2002040056A2 (en) * | 2000-11-06 | 2002-05-23 | Alcon, Inc | Carrageenan viscoelastics for ocular surgery |
| JP2003081841A (ja) * | 2001-06-26 | 2003-03-19 | Kikkoman Corp | 抗アレルギー体質強化剤 |
| TW200500085A (en) * | 2003-02-26 | 2005-01-01 | Otsuka Pharma Co Ltd | Sustained-release pharmaceutical composition for lung administration |
| EP1884245A1 (en) * | 2006-08-04 | 2008-02-06 | Marinomed Biotechnologie GmbH | Use of Escin |
| US20080131454A1 (en) * | 2006-12-05 | 2008-06-05 | Marinomed Biotechnologie Gmbh | Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan |
| NZ577063A (en) * | 2006-12-05 | 2011-05-27 | Marinomed Biotechnologie Gmbh | Use of iota-carrageenan for treating rhinovirus infections |
| EP1930015A1 (en) * | 2006-12-05 | 2008-06-11 | Marinomed Biotechnologie GmbH | Use of carrageenan for treating rhinovirus infections |
| EA018138B1 (ru) * | 2007-08-24 | 2013-05-30 | Мариномед Биотехнологи Гмбх | Применение йота-каррагенана в качестве противовирусного ингредиента |
-
2009
- 2009-06-30 JP JP2011515225A patent/JP5687619B2/ja active Active
- 2009-06-30 EP EP09772137.7A patent/EP2303287B1/en active Active
- 2009-06-30 PL PL09772137T patent/PL2303287T3/pl unknown
- 2009-06-30 EA EA201170117A patent/EA020222B1/ru unknown
- 2009-06-30 AU AU2009266076A patent/AU2009266076B2/en active Active
- 2009-06-30 US US12/992,424 patent/US20110091583A1/en not_active Abandoned
- 2009-06-30 HR HRP20140164AT patent/HRP20140164T1/hr unknown
- 2009-06-30 PT PT97721377T patent/PT2303287E/pt unknown
- 2009-06-30 CA CA2726221A patent/CA2726221C/en active Active
- 2009-06-30 MX MX2010013567A patent/MX2010013567A/es active IP Right Grant
- 2009-06-30 SG SG2013049085A patent/SG191697A1/en unknown
- 2009-06-30 ES ES09772137.7T patent/ES2445870T3/es active Active
- 2009-06-30 DK DK09772137.7T patent/DK2303287T3/en active
- 2009-06-30 BR BRPI0915119A patent/BRPI0915119B8/pt active IP Right Grant
- 2009-06-30 WO PCT/EP2009/004696 patent/WO2010000437A1/en not_active Ceased
- 2009-06-30 CN CN200980122094.7A patent/CN102065869B/zh active Active
- 2009-06-30 SI SI200930854T patent/SI2303287T1/sl unknown
- 2009-06-30 NZ NZ589293A patent/NZ589293A/xx unknown
-
2011
- 2011-09-19 US US13/236,056 patent/US20120058206A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010013567A (es) | 2011-01-21 |
| JP5687619B2 (ja) | 2015-03-18 |
| BRPI0915119B1 (pt) | 2021-02-17 |
| SI2303287T1 (sl) | 2014-04-30 |
| WO2010000437A1 (en) | 2010-01-07 |
| JP2012531382A (ja) | 2012-12-10 |
| DK2303287T3 (en) | 2014-02-17 |
| AU2009266076A1 (en) | 2010-01-07 |
| PT2303287E (pt) | 2014-02-27 |
| PL2303287T3 (pl) | 2014-05-30 |
| ES2445870T3 (es) | 2014-03-05 |
| CN102065869A (zh) | 2011-05-18 |
| EA020222B1 (ru) | 2014-09-30 |
| SG191697A1 (en) | 2013-07-31 |
| CN102065869B (zh) | 2014-10-08 |
| CA2726221A1 (en) | 2010-01-07 |
| HRP20140164T1 (hr) | 2014-04-11 |
| EA201170117A1 (ru) | 2011-06-30 |
| EP2303287B1 (en) | 2013-12-11 |
| NZ589293A (en) | 2012-09-28 |
| AU2009266076B2 (en) | 2015-05-21 |
| EP2303287A1 (en) | 2011-04-06 |
| US20110091583A1 (en) | 2011-04-21 |
| CA2726221C (en) | 2017-03-28 |
| US20120058206A1 (en) | 2012-03-08 |
| BRPI0915119A2 (pt) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0915119B8 (pt) | uso de iota carragenano | |
| BR112013022495A2 (pt) | formulação farmacêutica aquosa de tapentadol para administração oral | |
| BR112015007814A2 (pt) | diagnóstico, prevenção e tratamento de doenças da articulação | |
| BR112012026596A2 (pt) | método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas | |
| BR112016001446A8 (pt) | composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida | |
| MX2023006541A (es) | Formulaciones de dosis fija. | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| UA109661C2 (uk) | Фармацевтична композиція співкристалів трамадолу і коксибів | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| BR112012005044B8 (pt) | composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib | |
| BR112012012862A2 (pt) | composição farmacêutica compreendendo oligopeptídeos | |
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| BR112015014174A2 (pt) | composição de vacina para indivíduos virgens | |
| BR112013026698A2 (pt) | formulações do tipo tópica compreendendo depsipeptídeo cíclico | |
| BR112014016472A8 (pt) | formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo | |
| CO7101247A2 (es) | Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas | |
| BR112017009510A2 (pt) | composições compreendendo ciclosporina | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| UY33723A (es) | ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?. | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/02/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |